This comprehensive case study explores Kymanox’s approach to live microbial biologic development through end-to-end Chemistry Manufacturing Controls (CMC) oversight and technology transfer management. Our team of Subject Matter Experts (SMEs) collaborated closely with small biotech stakeholders to implement measurable improvements across Contract Development Manufacturing Organization (CDMO) relationship management, process development tech transfer, analytical method transfer, regulatory strategy, and clinical manufacturing readiness for genetically modified Bacillus Calmette-Guerin (BCG) based therapeutic development.
CHALLENGE
SOLUTION
RESULTS
- Small biotech company required comprehensive end-to-end CMC support and strategic oversight developing genetically modified BCG-based live microbial product for novel therapeutic application.
- Seamless process and analytical technology transfer to CDMO essential ensuring readiness for toxicology studies and Phase 1 clinical manufacturing.
- Regulatory strategy guidance, comprehensive documentation development, and effective relationship management critical across all development stages for resource-constrained organization.
- Phase-appropriate CMC regulatory strategy needed covering process development, toxicology manufacturing requirements, and Phase 1 clinical material production.
- Established strong collaborative working relationships between client and CDMO teams developing complete phase-appropriate CMC regulatory strategy covering process development through Phase 1 activities.
- Led comprehensive process and analytical tech transfer summarizing process development data, analytical methods, and Research and Development (R&D) manufacturing processes facilitating knowledge handoff.
- Transferred Research Cell Bank (RCB) to CDMO supporting adaptation to serum-free media platform and establishing Master Cell Bank (MCB) manufacturing strategy.
- Established analytical testing strategies, MCB characterization protocols, and stability programs aligned with regulatory guidance for live microbial biologics.
- Reviewed and optimized process development protocols, analytical methods, manufacturing batch records, Standard Operating Procedures (SOPs), and Bills of Materials (BoM).
- Negotiated contracts and quality agreements representing client interests and participated in weekly CDMO technical calls ensuring alignment and progress.
- Delivered comprehensive supporting documentation and strategic planning for Pre-Investigational New Drug (pIND) meeting package ensuring regulatory readiness.
- Successfully enabled completion of process development including four production runs with ongoing technical support ensuring process understanding and control.
- Achieved successful analytical method transfers, material transfers, and comprehensive tech transfer activities meeting critical project milestones.
- Produced material for non-GLP toxicology studies clearing key client milestones enabling regulatory advancement and clinical program progression.
- Established robust CDMO partnership and manufacturing capability supporting future toxicology and Phase 1 clinical material production requirements.
- Positioned client for successful regulatory interactions and clinical development advancement through comprehensive CMC strategy and documentation.